The mechanism of HLA-loss participating in leukemia relapse after haploidentical transplantation
-
-
关键词:
- HLA-loss /
- 单倍体相合造血干细胞移植 /
- 复发 /
- 急性白血病
Abstract: The loss of HLA molecule expression on tumor cells is one of the characteristics of immune escape. HLA-loss, genomic loss of a mismatched HLA haplotype, contributes to the escape of residual leukemic cells from immune surveillance and killing effect of donor T cells and thus induces leukemia relapse after haploidentical transplantation. HLA-loss has important clinical significance. It not only invalidates donor lymphocyte infusions used for prevention and treatment of post-transplantation relapse, but also increases the risk of graft versus host disease. This review focus on recent research of HLA-loss involved in relapse after haploidentical transplantation, which provides effective exploration on early diagnosis and treatment strategies for post-transplantation leukemia relapse. -
-
[1] 石威, 夏凌辉. 预防急性髓系白血病异基因造血干细胞移植术后复发[J]. 临床血液学杂志, 2021, 34(9): 618-622. http://lcxz.cbpt.cnki.net/WKC/WebPublication/paperDigest.aspx?paperID=11f7bcb8-d671-452c-978c-e4f827423c6d
[2] Ringdén O, Labopin M, Ciceri F, et al. Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings?[J]. Leukemia, 2016, 30(2): 447-455. doi: 10.1038/leu.2015.232
[3] D'Souza A, Fretham C, Lee SJ, et al. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States[J]. Biol Blood Marrow Transplant, 2020, 26(8): e177-e182. doi: 10.1016/j.bbmt.2020.04.013
[4] Horowitz M, Schreiber H, Elder A, et al. Epidemiology and biology of relapse after stem cell transplantation[J]. Bone Marrow Transplant, 2018, 53(11): 1379-1389. doi: 10.1038/s41409-018-0171-z
[5] Vago L, Perna SK, Zanussi M, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation[J]. N Engl J Med, 2009, 361(5): 478-488. doi: 10.1056/NEJMoa0811036
[6] Crucitti L, Crocchiolo R, Toffalori C, et al. Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation[J]. Leukemia, 2015, 29(5): 1143-1152. doi: 10.1038/leu.2014.314
[7] Masuda K, Hiraki A, Fujii N, et al. Loss or down-regulation of HLA class I expression at the allelic level in freshly isolated leukemic blasts[J]. Cancer Sci, 2007, 98(1): 102-108. doi: 10.1111/j.1349-7006.2006.00356.x
[8] Shyr DC, Zhang BM, Saini G, et al. HLA-haplotype loss after TCRalphabeta/CD19-depleted haploidentical HSCT[J]. Bone Marrow Transplant, 2021, 56(3): 733-737. doi: 10.1038/s41409-020-01081-0
[9] Hamdi A, Cao K, Poon LM, et al. Are changes in HLA Ags responsible for leukemia relapse after HLA-matched allogeneic hematopoietic SCT?[J]. Bone Marrow Transplant, 2015, 50(3): 411-413. doi: 10.1038/bmt.2014.285
[10] Segawa H, Kukita Y, Kato K. HLA genotyping by next-generation sequencing of complementary DNA[J]. BMC Genomics, 2017, 18(1): 914. doi: 10.1186/s12864-017-4300-7
[11] Ahci M, Toffalori C, Bouwmans E, et al. A new tool for rapid and reliable diagnosis of HLA loss relapses after HSCT[J]. Blood, 2017, 130(10): 1270-1273. doi: 10.1182/blood-2017-05-784306
[12] Ronaghy A, Yang RK, Khoury JD, et al. Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies[J]. Curr Hematol Malig Rep, 2020, 15(3): 194-202. doi: 10.1007/s11899-020-00578-1
[13] Schmid C, Labopin M, Nagler A, et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation[J]. Blood, 2012, 119(6): 1599-1606. doi: 10.1182/blood-2011-08-375840
[14] Rautenberg C, Germing U, Haas R, et al. Relapse of Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation: Prevention, Detection, and Treatment[J]. Int J Mol Sci, 2019, 20(1): 228. doi: 10.3390/ijms20010228
[15] Hirabayashi K, Kurata T, Horiuchi K, et al. Loss of Mismatched HLA on the Leukemic Blasts of Patients With Relapsed Lymphoid Malignancies Following Bone Marrow Transplantation From Related Donors With HLA Class Ⅱ Mismatches in the Graft Versus Host Direction[J]. Pediatr Blood Cancer, 2016, 63(4): 709-711. doi: 10.1002/pbc.25819
[16] Imus PH, Blackford AL, Bettinotti M, et al. Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation[J]. Biol Blood Marrow Transplant, 2017, 23(11): 1887-1894. doi: 10.1016/j.bbmt.2017.07.014
[17] Ikegame K, Kaida K, Fukunaga K, et al. Allogeneic hematopoietic stem cell transplantation from a 2-HLA-haplotype-mismatched family donor for posttransplant relapse: a prospective phase Ⅰ/Ⅱ study[J]. Bone Marrow Transplant, 2021, 56(1): 70-83. doi: 10.1038/s41409-020-0980-8
[18] Sano H, Mochizuki K, Kobayashi S, et al. Two Occurrences of Leukemia Relapse Due to Mismatched HLA Loss After Haploidentical Stem Cell Transplantation From Different Family Donors With KIR Ligand Mismatch[J]. J Pediatr Hematol Oncol, 2020, 42(2): e104-e106. doi: 10.1097/MPH.0000000000001443
[19] Locatelli F, Pende D, Falco M, et al. NK Cells Mediate a Crucial Graft-versus-Leukemia Effect in Haploidentical-HSCT to Cure High-Risk Acute Leukemia[J]. Trends Immunol, 2018, 39(7): 577-590. doi: 10.1016/j.it.2018.04.009
[20] Veluchamy JP, Kok N, van der Vliet HJ, et al. The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments[J]. Front Immunol, 2017, 8: 631. doi: 10.3389/fimmu.2017.00631
[21] 徐郑丽, 赵翔宇. 造血干细胞移植中KIR及其配体影响移植预后的研究进展[J]. 临床血液学杂志, 2021, 34(1): 71-75. http://lcxz.cbpt.cnki.net/WKC/WebPublication/paperDigest.aspx?paperID=f4f88507-9153-4b65-90d1-10c23965fea9
[22] Vago L, Forno B, Sormani MP, et al. Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation[J]. Blood, 2008, 112(8): 3488-3499. doi: 10.1182/blood-2007-07-103325
[23] Russo A, Oliveira G, Berglund S, et al. NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications[J]. Blood, 2018, 131(2): 247-262. doi: 10.1182/blood-2017-05-780668
[24] Gambacorta V, Oliveira G, Zito L, et al. HLA Loss Leukemia Relapses after Partially-Incompatible Allogeneic HSCT As a Prototypical System to Investigate Natural Killer Cell Dynamics[J]. Blood, 2015, 126(23): 743. doi: 10.1182/blood.V126.23.743.743
[25] Ciurea SO, Schafer JR, Bassett R, et al. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation[J]. Blood, 2017, 130(16): 1857-1868. doi: 10.1182/blood-2017-05-785659
[26] Rovatti PE, Zito L, Draghi E, et al. Exploiting an Anti-CD3/CD33 Bispecific Antibody to Redirect Donor T Cells Against HLA Loss Leukemia Relapses[J]. Blood, 2019, 134: 513. doi: 10.1182/blood-2019-126641
[27] Mo XD, Wang Y, Zhang XH, et al. Interferon-alpha Is Effective for Treatment of Minimal Residual Disease in Patients with t(8;21) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Registry Study[J]. Oncologist, 2018, 23(11): 1349-1357. doi: 10.1634/theoncologist.2017-0692
-
计量
- 文章访问数: 2517
- PDF下载数: 2937
- 施引文献: 0
下载: